At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Glutamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer
In Brief
A Phase 2 clinical trial evaluating Glutamine and Placebo for Kidney Cancer and 5 related conditions. Completed, enrolled 56 participants across 1 site.
Detailed Summary
RATIONALE: Glutamine may help lessen neuropathy caused by chemotherapy. It is not yet known whether glutamine is more effective than a placebo in treating neuropathy caused by vincristine. PURPOSE: This randomized phase II trial is studying glutamine to see how well it works compared to a placebo in treating neuropathy caused by vincristine in young patients with lymphoma, leukemia, or solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
First PostedAug 2006
Primary CompletionJun 2012
TodayJul 2026
First PostedAug 17, 2006
Enrollment StartOct 1, 2004
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 19.9 years ago
Interventions
Glutaminedrug
Administered orally twice daily for 21 days
Placeboother
Administered orally twice daily for 21 days